The PEPTIDE AND PROTEIN TECHNOLOGIES group's research focuses on the discovery, development and manufacture of peptides, proteins, antibodies, biosimilars and cell therapies for therapeutic and diagnostic applications. Its areas of expertise include antiviral drug discovery, peptide synthesis, recombinant technologies, immune and cell therapies, mass spectroscopy and bioanalysis. 

The development of biopharmaceutical processes is a crucial research area for our institute. This involves developing methods to produce drugs from biological materials, such as cells, tissues or living organisms. Thanks to this research, new treatments can be developed for diseases that are difficult to cure.

Areas of expertise

  • Recombinant proteins
  • Discovery of antiviral drugs
  • Synthesis of peptides, peptidomimetics, peptide and antibody conjugates
  • Tests for diagnostic applications
  • Immune and cellular therapies 
  • Mass spectroscopy and bioanalysis (ISO 17025)

Research areas

  • Development of biopharmaceuticals (USP, DSP)
  • Discovery and development of antiviral peptides (RSV, SARS-CoV-2), antibacterial cyclodepsipeptides, and glycosidase and glycosyltransferase inhibitors
  • Antibody delivery methods (conjugations)
  • Development and validation of bioanalytical methods (CE, LC-MS) for the characterisation and quantification of biomolecules
  • Creation of stable mammalian cell lines, development and optimisation of processes for the production of monoclonal, bi- and tri-specific antibodies and biosimilars
  • Development of cell-based therapies (e.g. CAR T)
  • Pegylated and polyethylenimine conjugated peptides for immunotherapy applications 

Senior researchers